Dianicline

Dianicline
Clinical data
ATC code none
Identifiers
CAS Number 292634-27-6 YesY
PubChem (CID) 9816447
ChemSpider 8352269 N
UNII Y0SNM34C6O YesY
ChEMBL CHEMBL187927 N
Chemical and physical data
Formula C13H16N2O
Molar mass 216.278
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Dianicline (SSR-591,813) is a drug developed by Sanofi-Aventis which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the α4β2 subtype. It is being developed as a medication for the treatment of nicotine dependence to assist in smoking cessation.[1] Dianicline is very similar to the already marketed drug varenicline and it is unclear what advantages it will have over the older drug, although it may have an improved side effect profile. It has been through human trials up to Phase II, although results have not yet been reported. Drug development has been discontinued after reporting of unfavourable results during Phase III trials.[2][3][4]

References

  1. Cohen C, Bergis OE, Galli F, Lochead AW, Jegham S, Biton B, Leonardon J, Avenet P, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Voltz C, Gardes A, Caille D, Perrault G, George P, Soubrie P, Scatton B. SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. Journal of Pharmacology and Experimental Therapeutics. 2003 Jul;306(1):407-20. PMID 12682217
  2. Fagerström K, Balfour DJK. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opinion on Investigational Drugs. 2006; 15(2):107-116.
  3. Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking Cessation
  4. Sanofi Pipeline

This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.